AR088970A1 - Derivados de [1,2,3]triazolo[4,5-d]pirimidina - Google Patents
Derivados de [1,2,3]triazolo[4,5-d]pirimidinaInfo
- Publication number
- AR088970A1 AR088970A1 ARP120104410A ARP120104410A AR088970A1 AR 088970 A1 AR088970 A1 AR 088970A1 AR P120104410 A ARP120104410 A AR P120104410A AR P120104410 A ARP120104410 A AR P120104410A AR 088970 A1 AR088970 A1 AR 088970A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- alkyl
- heterocyclyl
- heteroalkyl
- alkoxy
- Prior art date
Links
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title 1
- -1 haloalkylphenyl Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000005036 alkoxyphenyl group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000004069 aziridinyl group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004802 cyanophenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000003838 furazanyl group Chemical group 0.000 abstract 1
- 125000006485 halo alkoxy phenyl group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005216 haloheteroaryl group Chemical group 0.000 abstract 1
- 125000005059 halophenyl group Chemical group 0.000 abstract 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000005961 oxazepanyl group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001984 thiazolidinyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) en la que: A es alquileno, hidroxialquileno, -CH₂C(O)-, -C(O)-, -SO₂- o está ausente; R¹ es hidrógeno, alquilo, haloalquilo, hidroxilo, alcoxi, haloalcoxi, fenilo, halofenilo, alcoxifenilo, haloalquilfenilo, haloalcoxifenilo, cianofenilo, hidroxialcoxifenilo, alquilsulfonilfenilo, alquilsulfonilaminofenilo, (halo)(haloalquil)fenilo, (halo)(alcoxi)fenilo, ciano, cicloalquilo, cicloalquilalcoxi, amino, heterociclilo, alquilheterociclilo, hidroxiheterociclilo, alquilheterociclilo, heteroarilo, haloheteroarilo, alquilheteroarilo, (alquil)(alquilsulfonil)heteroarilo, (halo)(alquilamino)heteroarilo, haloalquilheteroarilo, cicloalquilheteroarilo o nitro-benzo[1,2,5]oxadiazolil-aminoheteroarilo, dicho heterociclilo es un anillo carbocíclico de tres a ocho eslabones que contiene por lo menos un átomo de nitrógeno o de oxígeno, y dicho heteroarilo es piridinilo, pirazolilo, oxadiazolilo, furazanilo, tetrazolilo, triazolilo o oxipiridinilo; R² es alquilo, haloalquilo, hidroxialquilo, alcoxialquilo, cicloalquilalcoxi, haloalcoxi, alcoxi o alquilamino; R³ es halógeno o -NR⁴R⁵; uno de R⁴ y R⁵ es hidrógeno o alquilo y el otro es alquilo o cicloalquilo; o R⁴ y R⁵ junto con el átomo de nitrógeno al que están unidos forman un heterociclilo o heterociclilo sustituido, dicho heterociclilo es morfolinilo, piperidinilo, piperazinilo, pirrolidinilo, 2-oxa-6-azaespiro[3.3]heptilo, azetidinilo, tiazolidinilo, tiomorfolinilo, dioxotiomorfolinilo, oxazepanilo, 2-oxa-6-azaespiro[3.4]octilo, 6-oxa-1-azaespiro[3.3]heptilo, 2-oxa-5-aza-espiro[3.4]-octilo, isoxazolidinilo, aziridinilo o dioxoisotiazolidinilo y dicho heterociclilo sustituido es un heterociclilo sustituido de una a cuatro veces por sustituyentes elegidos con independencia entre alquilo, halógeno, hidroxilo, alcoxi, hidroxialquilo, carboxilo, alcoxialquilo, ciano y alquilcarbonilamino; o una sal o un éster farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11190777 | 2011-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088970A1 true AR088970A1 (es) | 2014-07-23 |
Family
ID=47278275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104410A AR088970A1 (es) | 2011-11-25 | 2012-11-23 | Derivados de [1,2,3]triazolo[4,5-d]pirimidina |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9067943B2 (es) |
| EP (1) | EP2782915B1 (es) |
| JP (1) | JP6077558B2 (es) |
| KR (1) | KR20140097201A (es) |
| CN (1) | CN104039791B (es) |
| AR (1) | AR088970A1 (es) |
| AU (1) | AU2012342471B2 (es) |
| BR (1) | BR112014012479A2 (es) |
| CA (1) | CA2850697A1 (es) |
| CL (1) | CL2014001309A1 (es) |
| CO (1) | CO6930360A2 (es) |
| CR (1) | CR20140222A (es) |
| CY (1) | CY1116984T1 (es) |
| DK (1) | DK2782915T3 (es) |
| EA (1) | EA024108B1 (es) |
| ES (1) | ES2550967T3 (es) |
| HR (1) | HRP20151423T1 (es) |
| HU (1) | HUE028020T2 (es) |
| IL (1) | IL232304A (es) |
| MA (1) | MA35663B1 (es) |
| MX (1) | MX346248B (es) |
| PE (1) | PE20141578A1 (es) |
| PH (1) | PH12014501026A1 (es) |
| PL (1) | PL2782915T3 (es) |
| PT (1) | PT2782915E (es) |
| RS (1) | RS54319B1 (es) |
| SG (1) | SG11201402198XA (es) |
| SI (1) | SI2782915T1 (es) |
| TW (1) | TWI598350B (es) |
| UA (1) | UA111643C2 (es) |
| WO (1) | WO2013076182A1 (es) |
| ZA (1) | ZA201403441B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
| MX391724B (es) | 2013-09-06 | 2025-03-21 | Hoffmann La Roche | Nuevos derivados de triazolo[4,5-d]pirimidina. |
| EA031735B1 (ru) | 2014-11-07 | 2019-02-28 | Ф. Хоффманн-Ля Рош Аг | ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2 |
| WO2017004133A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2018015088A1 (en) * | 2016-06-23 | 2018-01-25 | F. Hoffmann-La Roche Ag | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives |
| WO2017220516A1 (en) * | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| KR20230062680A (ko) * | 2016-06-23 | 2023-05-09 | 에프. 호프만-라 로슈 아게 | 2형 칸나비노이드 수용체에 대한 친화성을 갖는 [1,2,3]트라이아졸로[4,5-d]피리미딘 유도체 |
| WO2017220544A1 (en) * | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| CN112533913A (zh) * | 2018-05-04 | 2021-03-19 | 英夫拉索姆有限公司 | 新颖化合物 |
| CN112007156A (zh) * | 2019-05-30 | 2020-12-01 | 复旦大学 | 大麻素受体药物在制备治疗心肌细胞坏死性凋亡药剂中的应用 |
| CN112755189A (zh) * | 2019-11-02 | 2021-05-07 | 复旦大学 | 1型大麻素受体拮抗剂在制备治疗心肌细胞焦亡药剂中的应用 |
| WO2023072978A1 (en) * | 2021-10-28 | 2023-05-04 | F. Hoffmann-La Roche Ag | Synthesis of [1,2,3]triazolo[4,5-d]pyrimidines |
| CN115246832B (zh) * | 2022-06-15 | 2024-05-24 | 深圳湾实验室 | 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2543333A (en) * | 1950-02-02 | 1951-02-27 | American Cyanamid Co | Derivatives of upsilon-triazolo (d) pyrimidine and methods of preparing the same |
| US4157443A (en) * | 1976-11-11 | 1979-06-05 | Ciba-Geigy Corporation | V-Triazolyl-[4,5-d]-pyrimidines |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| WO2005061505A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Bicyclic imidazolyl pyrimidin-4-one cannabinoid receptor ligands and uses thereof |
| DE102004014534A1 (de) * | 2004-03-23 | 2005-10-13 | Basf Ag | Triazolderivate und Verwendung von Triazolderivaten in organischen Leuchtdioden (OLEDs) |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| EP2070927A4 (en) | 2006-09-13 | 2010-10-13 | Kyowa Hakko Kirin Co Ltd | CONDENSED HETEROCYCLIC DERIVATIVE |
| US20100197692A1 (en) * | 2007-07-20 | 2010-08-05 | Merck Frosst Canada Ltd. | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| UA104010C2 (en) * | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
| MX2012011164A (es) | 2010-03-31 | 2012-11-12 | Lilly Co Eli | Compuesto de purina usados como agonistas de cb2. |
| AR080711A1 (es) * | 2010-03-31 | 2012-05-02 | Lilly Co Eli | Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor |
| UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
-
2012
- 2012-11-19 US US13/680,143 patent/US9067943B2/en not_active Expired - Fee Related
- 2012-11-21 TW TW101143551A patent/TWI598350B/zh active
- 2012-11-22 SG SG11201402198XA patent/SG11201402198XA/en unknown
- 2012-11-22 PT PT127946846T patent/PT2782915E/pt unknown
- 2012-11-22 EA EA201491002A patent/EA024108B1/ru not_active IP Right Cessation
- 2012-11-22 AU AU2012342471A patent/AU2012342471B2/en not_active Ceased
- 2012-11-22 PE PE2014000737A patent/PE20141578A1/es not_active Application Discontinuation
- 2012-11-22 JP JP2014542823A patent/JP6077558B2/ja not_active Expired - Fee Related
- 2012-11-22 KR KR1020147013833A patent/KR20140097201A/ko not_active Ceased
- 2012-11-22 EP EP12794684.6A patent/EP2782915B1/en not_active Not-in-force
- 2012-11-22 ES ES12794684.6T patent/ES2550967T3/es active Active
- 2012-11-22 BR BR112014012479A patent/BR112014012479A2/pt not_active IP Right Cessation
- 2012-11-22 MX MX2014005692A patent/MX346248B/es active IP Right Grant
- 2012-11-22 PH PH1/2014/501026A patent/PH12014501026A1/en unknown
- 2012-11-22 SI SI201230351T patent/SI2782915T1/sl unknown
- 2012-11-22 DK DK12794684.6T patent/DK2782915T3/en active
- 2012-11-22 CA CA2850697A patent/CA2850697A1/en not_active Abandoned
- 2012-11-22 WO PCT/EP2012/073315 patent/WO2013076182A1/en not_active Ceased
- 2012-11-22 PL PL12794684T patent/PL2782915T3/pl unknown
- 2012-11-22 HU HUE12794684A patent/HUE028020T2/en unknown
- 2012-11-22 UA UAA201407119A patent/UA111643C2/uk unknown
- 2012-11-22 RS RS20150674A patent/RS54319B1/sr unknown
- 2012-11-22 HR HRP20151423TT patent/HRP20151423T1/hr unknown
- 2012-11-22 CN CN201280057272.4A patent/CN104039791B/zh not_active Expired - Fee Related
- 2012-11-23 AR ARP120104410A patent/AR088970A1/es unknown
-
2014
- 2014-03-31 CO CO14068511A patent/CO6930360A2/es unknown
- 2014-04-28 IL IL232304A patent/IL232304A/en not_active IP Right Cessation
- 2014-05-13 CR CR20140222A patent/CR20140222A/es unknown
- 2014-05-13 ZA ZA2014/03441A patent/ZA201403441B/en unknown
- 2014-05-19 CL CL2014001309A patent/CL2014001309A1/es unknown
- 2014-05-27 MA MA37073A patent/MA35663B1/fr unknown
-
2015
- 2015-11-27 CY CY20151101081T patent/CY1116984T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088970A1 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina | |
| AR088663A1 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina agonistas de receptores canabinoides | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| AR095280A1 (es) | Derivados heterocíclicos de imidazo[1,2-a]piridina | |
| AR078841A1 (es) | Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10 | |
| AR093804A1 (es) | Derivados de pirazina agonistas de receptores cb2 | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR083813A1 (es) | Derivados de pirazol aminopirimidina como moduladores de lrrk2 | |
| AR093806A1 (es) | Derivados de piridina agonistas de receptores cb2 | |
| AR059686A1 (es) | Piperazinas terapeuticas | |
| AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
| JP2017222709A5 (es) | ||
| PE20200739A1 (es) | Pirrolopirimidinas como potenciadores de cftr | |
| AR060537A1 (es) | 1,2,4-triazoles trisustituidos | |
| ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| AR092490A2 (es) | Indolil alquil amino derivados sustituidos como inhibidores de la histona desacetilasa | |
| AR064619A1 (es) | Derivados de amino-imidazopiridinas, composiciones farmaceuticas que los contienen y usos de los mismos como agentes antitumorales. | |
| PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR079904A1 (es) | Derivados de triazol sustituidos como moduladores de la gamma secretasa | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR093805A1 (es) | Derivados de piridina agonistas del receptor 2 de cannabinoides | |
| AR086198A1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |